for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

メルク・アンド・カンパニー・インク

MRK.N

現在値

73.42USD

変化

0.08(+0.11%)

出来高

2,997,067

本日のレンジ

72.80

 - 

73.84

52週レンジ

70.90

 - 

91.40

∙ 約20分前の相場を表示しています。

適時開示

FDA Approves Merck’s KEYTRUDA (Pembrolizumab) As Adjuvant Treatment For Adult And Pediatric Patients

Dec 3 (Reuters) - Merck & Co Inc <MRK.N>::FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) AS ADJUVANT TREATMENT FOR ADULT AND PEDIATRIC (≥12 YEARS OF AGE) PATIENTS WITH STAGE IIB OR IIC MELANOMA FOLLOWING COMPLETE RESECTION.

Merck Japan Applies For Approval Of Molnupiravir Covid-19 Oral Therapy Drug - Nikkei

Dec 3 (Reuters) - :MERCK JAPAN APPLIES FOR APPROVAL OF MOLNUPIRAVIR COVID-19 ORAL THERAPY DRUG - NIKKEI.Further company coverage: MRK.N.

Merck Says U.S. FDA Accepts For Priority Review The Supplemental BLA For Vaxneuvance

Dec 1 (Reuters) - Merck & Co Inc <MRK.N>::U.S. FDA ACCEPTS FOR PRIORITY REVIEW THE SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR MERCK’S VAXNEUVANCE™ (PNEUMOCOCCAL 15-VALENT CONJUGATE VACCINE) FOR USE IN INFANTS AND CHILDREN.MERCK & CO INC - FDA SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA), OR TARGET ACTION DATE, OF APRIL 1, 2022 FOR VAXNEUVANCE.

Merck's Keytruda Approved In Japan In Combination With Chemotherapy For Esophageal Carcinoma

Nov 30 (Reuters) - Merck & Co Inc <MRK.N>::MERCK’S KEYTRUDA® (PEMBROLIZUMAB) APPROVED IN JAPAN IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PATIENTS WITH RADICALLY UNRESECTABLE, ADVANCED OR RECURRENT ESOPHAGEAL CARCINOMA.MERCK & CO INC - JAPANESE PACKAGE INSERT NOTES THAT IN KEYNOTE-590, ADVERSE REACTIONS WERE OBSERVED IN 364 PATIENTS.MERCK - IN KEYNOTE-590 TRIAL, KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENTS IN OVERALL SURVIVAL.

Merck Says FDA Accepts Submission Of sNDA For Lynparza As Treatment Breast Cancer, Grants Priority Review

Nov 30 (Reuters) - Merck & Co Inc <MRK.N>::FDA ACCEPTS REGULATORY SUBMISSION OF SUPPLEMENTAL NEW DRUG APPLICATION FOR LYNPARZA® (OLAPARIB) AS ADJUVANT TREATMENT IN BRCA-MUTATED, HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER AND GRANTS PRIORITY REVIEW.

U.S. FDA Publishes Briefing Documents On Merck's Covid-19 Pill

Nov 26 (Reuters) - U.S. Food and Drug Administration::U.S. FDA PUBLISHES BRIEFING DOCUMENTS ON MERCK & CO INC'S COVID-19 PILL.

Merck And Ridgeback Biotherapeutics Provide Update On COVID-19 Treatment

Nov 26 (Reuters) - Merck & Co Inc <MRK.N>::MERCK AND RIDGEBACK BIOTHERAPEUTICS PROVIDE UPDATE ON RESULTS FROM MOVE-OUT STUDY OF MOLNUPIRAVIR, AN INVESTIGATIONAL ORAL ANTIVIRAL MEDICINE, IN AT RISK ADULTS WITH MILD-TO-MODERATE COVID-19.MERCK & CO INC - NINE DEATHS WERE REPORTED IN PLACEBO GROUP, AND ONE IN MOLNUPIRAVIR GROUP.MERCK & CO INC - ADVERSE EVENT PROFILE FOR MOLNUPIRAVIR REMAINED CONSISTENT WITH PROFILE REPORTED AT PLANNED INTERIM ANALYSIS.MERCK - IN THIS STUDY POPULATION, MOLNUPIRAVIR REDUCED RISK OF HOSPITALIZATION OR DEATH FROM 9.7% IN PLACEBO GROUP TO 6.8% IN MOLNUPIRAVIR GROUP.MERCK - INTERIM ANALYSIS AND ADDITIONAL ANALYSES SUPPORT EFFICACY AND OVERALL FAVORABLE BENEFIT-RISK ASSESSMENT OF MOLNUPIRAVIR.MERCK - HAS SHARED ADDITIONAL ANALYSES WITH FDA, WILL BE PRESENTED TO FDA'S ANTIMICROBIAL DRUGS ADVISORY COMMITTEE ON NOV. 30.

Health Canada Approves Keytruda In Combination With Chemotherapy For Treatment Of Certain Type Of Breast Cancer

Nov 23 (Reuters) - Merck & Co Inc <MRK.N>::HEALTH CANADA APPROVES KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH CHEMOTHERAPY FOR THE TREATMENT OF LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHOSE TUMORS EXPRESS PD-L1 (CPS ≥10).MERCK CANADA - CONDITIONAL APPROVAL BASED ON DATA FROM PHASE 3 KEYNOTE-355 TRIAL; INTRODUCES FIRST BREAST CANCER INDICATION FOR KEYTRUDA.

EMA's CHMP Starts Evaluating Marketing Authorisation Application For Merck's Lagevrio

Nov 23 (Reuters) - European Medicines Agency::EMA: EMA’S CHMP STARTED EVALUATING THE MARKETING AUTHORISATION APPLICATION FOR LAGEVRIO (MOLNUPIRAVIR): 23/11/2021.EMA: EMA WILL ASSESS THE BENEFITS AND RISKS OF LAGEVRIO UNDER A REDUCED TIMELINE.EMA: COULD ISSUE OPINION WITHIN WEEKS IF DATA SUBMITTED ARE SUFFICIENTLY ROBUST AND COMPLETE TO SHOW THE EFFICACY, SAFETY AND QUALITY OF THE MEDICINE. ((Reuters.Briefs@thomsonreuters.com;)).

EMA Issues Advice On Use Of Lagevrio (Molnupiravir) For Treatment Of COVID-19

Nov 19 (Reuters) - EMA: :EMA: EMA ISSUES ADVICE ON USE OF LAGEVRIO (MOLNUPIRAVIR) FOR THE TREATMENT OF COVID-19: 19/11/2021.EMA: LAGEVRIO (MOLNUPIRAVIR) WHICH IS AVAILABLE AS CAPSULES, SHOULD BE TAKEN TWICE A DAY FOR 5 DAYS.EMA - LAGEVRIO CAN BE USED TO TREAT ADULTS WITH COVID-19 WHO DO NOT NEED SUPPLEMENTAL OXYGEN & WHO ARE AT INCREASED RISK OF DEVELOPING SEVERE COVID-19.EMA SAYS ADVICE FOLLOWS A REVIEW OF DATA, INCLUDING DATA ON MEDICINE'S QUALITY AND RESULTS FROM COMPLETED AND ONGOING STUDIES.EMA: LAGEVRIO IS NOT RECOMMENDED DURING PREGNANCY AND IN WOMEN WHO CAN BECOME PREGNANT AND ARE NOT USING EFFECTIVE CONTRACEPTION.EMA: WOMEN WHO CAN BECOME PREGNANT MUST USE EFFECTIVE CONTRACEPTION DURING TREATMENT AND FOR 4 DAYS AFTER THE LAST DOSE OF LAGEVRIO.EMA SAYS BREASTFEEDING SHOULD BE INTERRUPTED DURING TREATMENT WITH LAGEVRIO AND FOR 4 DAYS AFTER TREATMENT.EMA SAYS ADVICE CAN NOW BE USED TO SUPPORT NATIONAL RECOMMENDATIONS ON POSSIBLE USE OF MEDICINE BEFORE MARKETING AUTHORISATION..EMA SAYS LAGEVRIO SHOULD BE ADMINISTERED AS SOON AS POSSIBLE AFTER DIAGNOSIS OF COVID-19 AND WITHIN 5 DAYS OF START OF SYMPTOMS..Further company coverage: MRK.N. ((Reuters.Briefs@thomsonreuters.com;;)).

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up